Intranasal Insulin and Memory in Early Alzheimer's Disease
Overview
- Phase
- Phase 1
- Intervention
- Insulin Aspart
- Conditions
- Alzheimer's Disease
- Sponsor
- Jeff Burns, MD
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- fMRI Measure of Hippocampal Activation
- Status
- Completed
- Last Updated
- 10 years ago
Overview
Brief Summary
To determine which parts of the brain are involved in insulin-related memory improvement in early Alzheimer's disease and cognitively normal older adults.
Detailed Description
Functional MRI study to characterize the neuroanatomic correlates of acute exogenous insulin-related improvements in cognitive performance in early Alzheimer's disease and cognitively normal older adults. The role of the apoE-e4 allele in modulating brain insulin responses is also addressed.
Investigators
Jeff Burns, MD
Professor, Associate Director University of Kansas Alzheimer's Disease Center
University of Kansas Medical Center
Eligibility Criteria
Inclusion Criteria
- •Patients with Early Alzheimer's disease
Exclusion Criteria
- •Patients with Late Alzheimer's disease
Arms & Interventions
Intranasal Insulin Aspart
Participants were administered intranasal insulin aspart (40 IU) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
Intervention: Insulin Aspart
Intranasal Saline (placebo)
Participants were administered intranasal saline (placebo) in a double-blinded fashion approximately 30 minutes prior to functional MRI scanning. After a washout period of 48 hours, participants completed the other arm. The order of saline vs. insulin was counterbalanced.
Intervention: Placebo
Outcomes
Primary Outcomes
fMRI Measure of Hippocampal Activation
Time Frame: 30 minutes After Intervention Administration
Percentage active voxels of total hippocampal volume of interest
Secondary Outcomes
- Global Cognition(90 mins)